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Overactivity of the immune system may be a worthwhile therapeutic target for implementing
prognostic improvements. Therefore the impact of lipopolysaccharide (LPS) desensitization on
survival may help in the development of novel therapies. An understanding of the pathophy-
siology of the trace element selenium may complement such approaches, as recent data
suggest that inﬂammatory responses are selenium-dependent.
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inﬂammatory responses are selenium-dependent (Curran
et al., 2005; Stoedter et al., 2010). We hypothesized that
lower LPS reactivity would be associated with worse survival
as compared to normal or higher LPS reactivity in patients
with chronic HF. In addition, we sought to elucidate the role
of the selenium status in this context.
LPS responsiveness was studied in 122 patients with
chronic HF (mean7SD: age 67.3710.3 years, 24 female,
New York Heart Association class [NYHA] class: 2.570.8, left
ventricular ejection fraction [LVEF]: 33.5712.5%) and 27
control subjects of similar age (63.777.7 years, p40.05).
Reference LPS was added at increasing doses to ex vivo whole
blood samples and tumour necrosis factor-α (TNFα) was
measured. Patients were subgrouped into good- and poor-
responder status according to their potential to react to
increasing doses of LPS (delta TNFα secretion). The optimal
cut-off value was calculated by receiver-operator character-
istic curve (ROC) analysis.
Serum selenium ranged from 51 to 318 μg/L in both
groups with signiﬁcantly lower levels in patients with
chronic HF than in controls (po0.05). A total of 56 patients
with chronic HF died from any cause during follow-up.
At 12, 24, 36, and 48 months, cumulative mortality was
10.7% (95% CI 10.4–11.0%), 16.4% (95% CI 16.0–16.7%), 25.4
(95% CI 21.5–25.8%), and 32.0% (95% CI 31.6–32.4%), respec-
tively. At 24 months, the delta TNFα value representing the
optimal cut-off for the prediction of mortality was 1522 pg/mL,
and it was associated with a sensitivity of 49.3% (95% CI 37.
2–61.4%) and a speciﬁcity of 81.5% (95% CI 61.9–93.6%).
According to this cut-off value, 51 patients (45%) were deﬁned
as good-, and 62 (55%) as poor-responders. In patients with HF,
serum selenium was signiﬁcantly higher in good-responders
compared to poor-responders (po0.05). LPS responder status
remained an independent predictor of death after multivariable
adjustment (hazard ratio 0.09 for good- vs. poor-responders,
95% CI 0.01-0.67, po0.05).
We have shown that the responsiveness towards LPS as
assessed by TNFα secretion is an independent predictor of
death. Additionally, serum selenium appears to play an
important role in immune function and HF-dependent
survival. These ﬁndings are in line with other studies
(Alexanian et al., 2014; de Lorgeril and Salen, 2000;
Lymbury et al., 2010) highlighting the physiologicalimportance of the selenium status for the immune system
and HF-related mortality risk.
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